Takeda's Maribavir Reduces Hospitalization Rates, Hospital Stay In Post-Transplant Infection Patients
Takeda's Maribavir Reduces Hospitalization Rates, Hospital Stay In Post-Transplant Infection Patients
武田公司的Maribavir降低了移植後感染患者的住院率和住院時間
- Takeda Pharmaceutical Co Ltd (NYSE:TAK) shared new analyses of Livtencity (maribavir), including additional analyses from Phase 3 SOLSTICE trial data, which supported the FDA approval of Livtencity.
- Livtencity is approved in the U.S. for patients aged 12 years and above with post-transplant cytomegalovirus (CMV) infection/disease refractory to treatment.
- Data from an exploratory analysis of the Phase 3 SOLSTICE trial showed that 31.9% of patients treated with Livtencity had at least one hospitalization compared to 36.8% of patients treated with conventional therapies.
- Also Read: Takeda's Angioedema Drug Shows Promising Action Against COVID-19 Infection.
- The Livtencity treatment group had a 34.8% reduction over the conventional therapy group (p=0.021).
- The length of hospital stay during the treatment phase was 13.27 days/person/year in Livtencity-treated patients compared to 28.73 for those conventionally treated, a 53.8% decrease (p=0.029).
- Price Action: TAK shares are down 0.89% at $14.42 during the market session on the last check Friday.
- 武田藥品工業株式會社(紐約證券交易所股票代碼：TAK)分享了對Livtencity(Maribavir)的新分析，包括支持FDA批准Livtencity的3期至日試驗數據的其他分析。
- Livtencity在美國被批准用於12歲及以上患有移植後鉅細胞病毒(CMV)感染/難以治療的疾病的患者。
- 對3期Solstice試驗的探索性分析數據顯示，接受Livtencity治療的患者中有31.9%的患者至少住院一次，而接受傳統治療的患者中這一比例為36.8%。
- 另請閲讀： 武田的血管水腫藥顯示出對抗新冠肺炎感染的良好效果.
- Livtencity治療組比傳統治療組減少了34.8%(p=0.021)。
- 接受Livtencity治療的患者在治療階段的住院時間為13.27天/人/年，而接受常規治療的患者為28.73天/人/年，減少了53.8%(p=0.029)。
- 價格行動：德意志銀行股價週五尾盤下跌0.89%，至14.42美元。